XTRA:MRKPharmaceuticals
Merck KGaA (XTRA:MRK) Valuation Check After Mixed Earnings And Fertility Segment Growth
Merck KGaA (XTRA:MRK) is back in focus after mixed financial updates, with one quarter showing an 11.8% profit decline despite 5.3% net sales growth, and another highlighting 4.7% organic revenue growth and higher EBITDA.
See our latest analysis for Merck KGaA.
The recent mixed earnings messages seem to align with Merck KGaA’s price action, with a 10.3% 1 month share price return and a 10.5% 3 month share price return contrasting with a 1 year total shareholder return decline of 8.3%. This...